Eyenovia is a late-stage ophthalmic biopharmaceutical company developing breakthrough treatments for front and back-of-the-eye diseases, which are made possible by the companyâs transformative, high precision ophthalmic delivery platform. Eyenoviaâs pipeline is currently focused on the development of four programs including myopia (nearsightedness) progression, glaucoma and other eye diseases. Source
No articles found.
Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic a...
Lipocine Inc. is a clinical-stage biopharmaceut...
Amarin Corporation plc. is a rapidly growing, innovative pharmaceutical company fo...
Amarin Corporation plc. is a rapidly growing, i...
The recognized global leader in neuromodulation devices to treat blindness, the co...
The recognized global leader in neuromodulation...
Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-onco...
Leap Therapeutics (NASDAQ: LPTX) is focused on ...
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company targeting the ...
Salarius Pharmaceuticals, Inc. is a clinical-st...
We are Anchiano Therapeutics, a pivotal-stage biopharmaceutical company focused on...
We are Anchiano Therapeutics, a pivotal-stage b...
Join the National Investor Network and get the latest information with your interests in mind.